Pfizer has seen its revenue and earnings fluctuate over the past three years, driven largely by the expiration of key patents and uneven product approvals. The company faces a significant patent cliff in the next two years when exclusivity for its top-selling anticoagulant ends, putting pressure on overall top-line growth. Over the last twelve quarters, reported revenue swings have ranged from a 5% decline year-over-year to a 3% increase, highlighting the inconsistency that has weighed on investor confidence.

To counter looming patent expirations, Pfizer has invested heavily in R&D and bolt-on acquisitions, expanding its candidate roster across oncology, rare disease and metabolic disorders. Since 2023, the company has completed four acquisitions totaling more than $20 billion in enterprise value, adding three late-stage oncology assets and a promising weight-management peptide. Management forecasts at least five new product launches by 2030, with peak annual sales potential exceeding $5 billion per asset for its highest-priority oncology candidates.

Pfizer’s balance sheet remains conservative, with net debt around $30 billion and a gross margin above 68%, supporting a dividend that has grown by over 50% in the past decade. The current forward P/E ratio stands near 8.5x, well below the healthcare sector average of 18.4x, and the company yields nearly 7% on an annualized basis. Additionally, a three-year tariff exemption deal secured with the U.S. government removes potential cost headwinds, bolstering the stock’s attractiveness for income-focused investors seeking both yield and deep value exposure.